ACTR-65. SAFETY PROFILE OF TUMOR TREATING FIELDS IN ADULT GLIOBLASTOMA PATIENTS WITH IMPLANTED NON-PROGRAMMABLE SHUNTS PROGRAMMABLE SHUNTS AND PACEMAKERS/DEFIBRILLATORS: 6-YEAR UPDATED RETROSPECTIVE ANALYSIS OF OPTUNE® THERAPY

摘要

BACKGROUNDTumor Treating Fields (TTFields) are a noninvasive, loco-regional, anti-mitotic cancer treatment approved in the U.S. for adults with recurrent and newly diagnosed glioblastoma (GBM). TTFields (low intensity, intermediate frequency, alternating electric fields) are delivered by a portable medical device (Optune®). GBM patients may develop hydrocephalus and benefit from subsequent shunt placement. Safety information on concomitant use of TTFields with implanted devices in GBM patients will identify potential interference with the functioning of these devices.